InnoCan Pharma Corp (IP4.BE)

Innocan Pharma Announces Brokered LIFE Offering of Units for Up to $3 Million

NOT FOR DISSEMINATION IN OR INTO THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES HERZLIYA, Israel and CALGARY, Alberta, Sept. 21, 2023 (GLOBE NEWSWIRE) -- Innocan Pharma Corporation (the “Company”) (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) is pleased to announce that it has entered into an agreement with Research Capital Corporation as the sole agent and sole bookrunner (the “Agent”) on a “best efforts” agency basis in connection with a marketed private placement offering (the “Offer